A.I. Burnasyan FMBC clinical bulletin. 2022 № 3
J.S. Kitaeva1, E.A. Praskurnichy2, M.I. Pereginets1
REDUCTION OF BONE MINERAL DENSITY IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES
1Federal Educational Budgetary Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Yekaterinburg, Russia
2A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Kitaeva Yulia Sergeevna: JKhema@yandex.ru
Abstract
In recent years, the incidence of hemoblastoses has not changed significantly, but the mortality rate has decreased and the life expectancy of patients has increased. The prognosis of survival with these diseases using modern methods of treatment is relatively favorable. In most patients, after the use of standard first-line polychemotherapy, a cure is possible. Autologous hematopoietic stem cell transplantation is a modern and very effective method of treatment for relapsed or refractory course, the use of which is accompanied by an increase in the number of cured patients. However, an increase in the survival rate in lymphoproliferative diseases is associated with an increase in the likelihood of complications of previous cytostatic therapy, the frequency of patient disability or death. Among the many long-term complications of polychemotherapy and autologous hematopoietic stem cell transplantation, pathology of the musculoskeletal system is revealed, which develops as a result of metabolic bone lesions – osteoporosis and associated low-energy fractures. The mechanisms of osteoporosis development in patients with lymphoproliferative diseases are not well understood, however, there are a number of literature sources in which a decrease in bone mineral density is presented as a consequence of a violation of the formation and destruction of bone tissue, increased bone resorption. In turn, the reasons for the decrease in bone mineral density are the use of cytostatic drugs, glucocorticosteroids, nutritional deficiency, physical inactivity. In this context, the problems of diagnosing and preventing osteoporosis seem to be very relevant for modern oncohematology. The purpose of this literature review is to identify the main patterns of bone tissue processes in patients with lymphoproliferative diseases.
Keywords: lymphoproliferative disease, polychemotherapy, glucocorticosteroids, bone mineral density, osteoporosis
For citation: Kitaeva JS, Praskurnichy EA, Pereginets MI. Reduction of Bone Mineral Density in Patients with Lymphoproliferative Diseases f Bioimpedance Analysis in Clinical Practice: Literature Review. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2022.3:53-60. (In Russian) DOI: 10.33266/2782-6430-2022-3-53-60
REFERENCES
1. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Limfoproliferativnykh Zabolevaniy = Russian Clinical Guidelines for the Diagnosis and Treatment of Lymphoproliferative Diseases. Ed. Poddubnaya I.V., Savchenko V.G. Moscow, Buki Vedi Publ., 2016. 324 p. (In Russ.).
2. Bessmeltsev C.C., Abdulkadyrov K.M. Mnozhestvennaya Miyeloma = Multiple Myeloma. St. Petersburg, Dialekt Publ., 2004. 448 p. (In Russ.).
3. Voytko M.S., Pospelova T.I., Klimontov V.V., Mezit Ye.V. Actors Affecting Bone Remodeling in Patients with Hodgkin’s Lymphoma (Review). Sibirskiy Nauchnyy Meditsinskiy Zhurnal = Siberian Scientific Medical Journal. 2018;38;4:65-72 (In Russ.).
4. Ignatyeva Ye.V., Kryukov Ye.V., CHernetsov V.A., Rukavitsyn O.A. Comorbidity in Patients with Lymphoproliferative Diseases. Klinicheskaya Meditsina = Clinical Medicine. 2020;98;7:508–514 (In Russ.).
5. Skvortsova Yu.V., Balashov D.N., Skorobogatova Ye.V., et al. Bone Mineral Turnover after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Single Center Cohort Study. Pediatricheskaya Farmakologiya = Pediatric Pharmacology. 2017;14;6:459–468 (In Russ.).
6. Shakhtarina S.V., Danilenko A.A., Pavlov V.V., et al. Effects of Antitumor Chemotherapy and Radiation Therapy on Thyroid Gland in Hodgkin”s Lymphoma Patients During Follow-up Observations. Klinicheskaya Onkogematologiya. Fundamentalnyye Issledovaniya i Klinicheskaya Praktika = Clinical Oncohematology. 2014;7;4:532–538 (In Russ.).
7. Kanis J.A., World Health Organization. Centre for Metabolic Bone Diseases. Assessment of Osteoporosis at the Primary Health-Care Level: WHO Scientific Group Technical Report. Sheffi eld (UK), University of Sheffi eld (UK), Who Collaboraiting Centre, 2007.
8. Kanis J., Mccloskey E., Johansson H., et al. European Guidance for the Diagnosis and Management of Osteoporosis in Postmenopausal Women. Osteoporos Int. 2013;24;1:23-57.
9. Mikhaylov Ye.Ye., Benevolenskaya L.I. Rukovodstvo po Osteoporozu = Guide to Osteoporosis. Moscow, Binom. Laboratoriya Znaniy Publ., 2003 (In Russ.).
10. Lesnyak O.M., Yershova O.B. Audit Sostoyaniya Problemy Osteoporoza v Stranakh Vostochnoy Evropy i Tsentral’noy Azii 2010. Osteoporoz i Osteopatii = Osteoporosis and Bone Diseases. 2011;14;2:3-6 (In Russ.).
11. Ametov A.S. Izbrannyye Lektsii po Endokrinologii = Selected Lectures on Endocrinology. Moscow Publ., 2012 (In Russ.).
12. Kirvalidze N., Kilasonia L., Dolidze N., Lagvilava L. Does Osteoporosis Affect Young Men? Osteoporoz i Osteopatii = Osteoporosis and Bone Diseases. 2016;19;2:70-71.
13. Hans D., Barthe N., Boutroy S., et al. Correlations between Trabecular Bone Score, Measured Using Anteroposterior Dual-Energy X-Ray Absorptiometry Acquisition, and 3-Dimensional Parameters of Bone Microarchitecture: an Experimental Study on Human Cadaver Vertebrae. J. Clin Densitom. 2011;14;3:302–312.
14. Krug R., Carballido-Gamio J., Banerjee S., et al. In Vivo Ultra-Highfield Magnetic Resonance Imaging of Trabecular Bone Microarchitecture. J. Magn. Reson. Imaging. 2008. V.27. No. 4. P. 854–859
15. Sawada K., Morishige K.-I., Ohmichi M., et al. Peripheral Quantitative Computed Tomography (pQCT) is Useful for Monitoring Bone Mineral Density of the Patients Who Receive Hormone Replacement Therapy. J. Maturitas. 2007;56;4:343–349.
16. Kulak C.A., Dempster D.W. Bone Histomorphometry: a Concise Review for Endocrinologists and Clinicians. Arq. Bras. Endocrinol .Metabol. 2010;54;2:87–98.
17. Povoroznyuk V.V., Dzerovich N.I. Unified Questionnaires in the Diagnosis of Osteoporosis. Bol. Sustavy. Pozvonochnik = Pain. Joints. Spine. 2011;3 (In Ukr.).
18. Siminoski K., Jiang G., Adachi J.D., et al. Accuracy of Height Loss During Prospective Monitoring for Detection of Incident Vertebral Fractures. Osteoporos. Int. 2005;16;4:403-410.
19. Mazziotti G., Formenti A.M., Adler R.A., et al. Glucocorticoid-Induced Osteoporosis: Pathophysiological Role of GH/IGF-I and PTH/VITAMIN D Axes, Treatment Options and Guidelines. Endocrine. 2016;54;3:603–611.
20. Matheson E.C., Thomas H., Case M., et al. Glucocorticoids and Selumetinib are Highly Synergistic in RAS Pathwaymutated Childhood Acute Lymphoblastic Leukemia Through Upregulation of BIM. Haematologica. 2019;104;9:1804–1811.
21. Golds G., Houdek D., Arneson T. Male Hypogonadism and Osteoporosis: the Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health. Int. J. Endocrinol. 2017;1:1-15.
22. Golovach I.Yu. Osteoporosis and Osteoporotic Fractures Problems Related to Proton Pump Inhibitors Prolonged Use. Travma = Тrauma. 2016;5 (In Ukr.).
23. Boutroy S., Bouxsein M.L., Munoz F., Delmas P.D. In Vivo Assessment of Trabecular Bone Microarchitecture by High-Resolution Peripheral Quantitative Computed Tomography. J. Clin. Endocrinol. Metab. 2005;90;12:8–15.
24. Terpos E., Dimopoulos M.A. Myeloma Bone Disease: Pathophysiology and Management. Ann. Oncol. 2005;16;8:1223–1254.
25. Zatsepin S.T., Rodionova S.S., Bozhekov N.V., Lesnyak A.T. Differential Diagnosis of Systemic Osteoporosis and Myeloma. Ortopediya. 1987;11:46–49 (In Russ.).
26. Makarenko N.P. The Problem of Osteoporosis and the Possibility of Using Myocalcic in Oncology. Sovremennaya Onkologiya = Journal of Modern Oncology. 2000;2;2:59-60 (In Russ.).
27. Svistunov A.A., Ruta A.V., Shevchenko O.V. Peculiarities of Bone Metabolism in Patients with Multiple Myeloma. Saratovskiy Nauchno- Meditsinskiy Zhurnal = Saratov Journal of Medical Scientific Research. 2010;1:48-52 (In Russ.).
28. Benvenuti S., Brandi M. Corticosteroid-Inducid Osteoporosis:Pathogenesis and Revention. Clin. Exp. Pheumatol. 2000;18:64–69.
29. Terpos E., Dimopoulos M.A. Myeloma Bone Disease: Pathophysiology and Management. Ann. Oncol. 2005;16;8:1223–1254.
30. Musto P., Petrucci M.T., Bringhen S.A., et al. Multicenter, Randomized Clinical Trial Comparing Zoledronic Acid Versus Observation in Patients with Asymptomatic Myeloma. Cancer. 2008;113;7:1588–1595.
31. Chestnova T.V., Makarchev A.I., Korotkova A.S., Nazarova Ye.D. Multiple myeloma: difficulties in conducting a diagnostic search. Yevraziyskiy Soyuz Uchenykh = Eurasian Union of Scientists. 2019;8;65:41-46 (In Russ.).
32. Svistunov A.A., Ruta A.V., Shevchenko O.V. Peculiarities of Bone Metabolism in Patients with Multiple Myeloma. Saratovskiy Nauchno- Meditsinskiy Zhurnal = Saratov Journal of Medical Scientific Research. 2010;1:48-52 (In Russ.).
33. Geltser B.I., Zhilkova N.N., Anufriyeva N.D., Kochetkova Ye.A. Bone Lesions in Case of Multiple Myeloma. Tikhookeanskiy Meditsinskiy Zhurnal = Pacific Medical Journal. 2011;3;45:11–16 (In Russ.).
34. Krug R., Carballido-Gamio J., Banerjee S., et al. In Vivo Ultra-Highfield Magnetic Resonance Imaging of Trabecular Bone Microarchitecture. J. Magn. Reson. Imaging. 2008;24;4:4–9.
35. Ruchkin V.N., Gantsev K.Sh. Treatment of Bone Metastases in Cancer Patients. Kreativnaya Khirurgiya i Onkologiya = Creative Surgery and Oncology. 2010;2:78–83 (In Russ.).
36. Matlan V.L. Multiple Myeloma. Лiкувaння. 2006;1:3–10 (In Ukr.).
37. Shaforostova I.I., Remizov A.N., Tereshchenko G.V., Myakova N.V. Multifocal Bone Involvement in a Patient with Acute Lymphoblastic Leukemia. Voprosy Gematologii/Onkologii I Immunopatologii v Pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2015;14;1:62–63 (In Russ.).
38. Cohan N., Sarikhani S., Moslemi S., Karimi M. Initial Presentation of Acute Lymphoblastic Leukemia with Osteoporosis and Multiple Spontaneous Bone Fractures. Iranian Red. Crescent. Med. J. 2011;13:52–54.
39. Makitie O., Heikkinen R., Toiviainen-Salo S., Henriksson M., Puuko-Viertomies L.-R., Jahnukainen K. Long-Term Skeletal Consequences of Childhood Acute Lymphoblastic Leukemia in Adult Males: a Cohort Study. Eur. J. Endocrinol. 2013;168;2:281–288.
40. Ulanova A.S., Grigoryeva N.A., Turabov I.A., Rykov M.Yu. The Lesion of the Osteo-Articular System in the Onset of Acute Leukemia in Childhood. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2020;65;5:87–92 (In Russ.).
41. Seland M., Smeland K. B., Bjøro T., et al. Bone Mineral Density Is Close to Normal for Age in Long-Term Lymphoma Survivors Treated with High-Dose Therapy with Autologous Stem Cell Transplantation. ActaOncologica. 2017;56;4:590–598.
42. Inaba H., Cao X., Han A. Q., et al. Bone Mineral Density in Children with Acute Lymphoblastic Leukemia. Cancer. 2018;124;5:1025–1035.
43. Storck K., Brandstetter M., Keller U., Knopf A. Clinical Presentation and Characteristics of Lymphoma in the Head and Neck Region. Head Face Med. 2019;15;1.
44. Shahnazari B., Moghimi J., Foroutan M., et al. Comparison of the Effect of Vitamin D on Osteoporosis and Osteoporotic Patients with Healthy Individuals Referred to the Bone Density Measurement Center. Biomolecular Concepts. 2019;10;1:44–50.
45. Costa S., Reagan M. R. Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue. Front. Endocrinol (Lausanne). 2019;10.
46. Ghassemi A., Banihashem A., Ghaemi N., et al. Evaluation of Bone Mineral Density in Children with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL): Chemotherapy with/without Radiotherapy. Int. J. Hematol. Oncol. Stem. Cell. Res. 2016;10;3:53–160.
47. Volkova S.A., Borovkov N.N. Osnovy Klinicheskoy Gematologii = Fundamentals of Clinical Hematology. Textbook. Nizhniy Novgorod, NizhGMA Publ., 2013. P. 324-330 (In Russ.).
48. Rosenberg S.A., Diamond H.D., Jaslowitz B., Craver L.F. Lymphosarcoma: a Review of Cases. Medicine. 1961;40:31-84.
49. Vaturi M., Prokocimer M., Sidi Y. Hypercalcemia in chronical Lymphatic Leukemia Patients. Am. J. Hematol. 1996;53:245-247.
50. Ailawadhi S., Baddoura F.K., Haumesser J.C., et al. Hypercalcemia and Osteolytic Bone Lesions in B-Cell Chronic Lymphocytic Leukemia. A Case Report. Clin.Leuk. 2006;1;1:57-60.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 01.08.2022. Accepted for publication: 28.08.2022.